Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTUV8G9)

• DTT Name: Progesterone receptor (PGR)
• Synonyms: PR; Nuclear receptor subfamily 3 group C member 3; NR3C3
• Gene Name: PGR
• DTT Type: Successful target; [1]
• BioChemical Class: Nuclear hormone receptor
• UniProt ID: PRGR_HUMAN
• TTD ID: T22939
• Sequence:
  MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLF
  PRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLA
  PSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAA
  AHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGK
  PRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTV
  MDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPD
  CAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLG
  PPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPC
  KAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPP
  YLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHN
  YLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPV
  GVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQ
  LGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAP
  DLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQ
  FEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRA
  LSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK
• Function: Depending on the isoform, progesterone receptor functions as transcriptional activator or repressor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues.
• KEGG Pathway:
  Oocyte meiosis (hsa04114)
  Progesterone-mediated oocyte maturation (hsa04914)
• Reactome Pathway:
  Nuclear Receptor transcription pathway (R-HSA-383280)
  Nuclear signaling by ERBB4 (R-HSA-1251985)

Molecular Interaction Atlas (MIA) of This DTT

12 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[2]
Dydrogesterone	DMAKIDV	Menstrual disorder	GA20.3	Approved	[3]
Ethynodiol Diacetate	DMZM84R	Contraception	QA21	Approved	[4]
Etonogestrel	DMKA8J4	Contraception	QA21	Approved	[5]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[6]
Medroxyprogesterone	DMBGWPH	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Megestrol	DMDH9KX	Breast cancer	2C60-2C65	Approved	[7]
Norethindrone	DMTY169	Acne vulgaris	ED80	Approved	[8]
Norgestimate	DMYP4XC	Acne vulgaris	ED80	Approved	[5]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[1]
Segesterone acetate; ethinyl estradiol	DMFEGB0	Contraception	QA21	Approved	[9]
Ulipristal	DMBNI20	Contraception	QA21	Approved	[10]

11 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nestorone	DMVP7HI	Endometriosis	GA10	Phase 3	[11]
NPC-01	DMMC3Y8	Dysmenorrhea	GA34.3	Phase 3	[12]
BAY 86-5044	DMRZLU4	Breast cancer	2C60-2C65	Phase 2	[13]
MK-8342	DMD6E5W	Contraception	QA21	Phase 2	[14]
ONAPRISTONE	DMT6E5N	Breast cancer	2C60-2C65	Phase 2	[15]
S-PRAnt	DMFAO5G	Uterine fibroids	2E86.0	Phase 2	[16]
Telapristone	DM9AWSO	Endometriosis	GA10	Phase 2	[17]
Tosagestin	DM2HDTM	Contraception	QA21	Phase 2	[18]
Vilaprisan	DME7VZD	Endometriosis	GA10	Phase 2	[19]
Virexxa	DMEXMV5	Endometrial cancer	2C76	Phase 2	[14]
PF-2413873	DMCOUHT	Endometriosis	GA10	Phase 1	[20]

4 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Asoprisnil	DM4BV2W	Endometriosis	GA10	Discontinued in Phase 3	[21]
Org-31710	DMZKTU5	Contraception	QA21	Discontinued in Phase 1	[22]
BAY-39-9624	DMPUG18	Osteoporosis	FB83.0	Terminated	[23]
RU-46556	DM8B1DH	Endometrial cancer	2C76	Terminated	[24]

25 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione	DMV7UC0	Discovery agent	N.A.	Investigative	[25]
2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline	DMP9ECK	Discovery agent	N.A.	Investigative	[26]
2-(4-Amino-3'-chloro-biphenyl-3-yl)-propan-2-ol	DMSHPCW	Discovery agent	N.A.	Investigative	[27]
3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one	DMUS0A4	Discovery agent	N.A.	Investigative	[28]
3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile	DMSHORK	Discovery agent	N.A.	Investigative	[29]
3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione	DMEG3YX	Discovery agent	N.A.	Investigative	[25]
4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile	DMBLAI1	Discovery agent	N.A.	Investigative	[30]
5,N-Dihydroxythalidomide	DM3MSZN	Discovery agent	N.A.	Investigative	[25]
5-(2-oxoindolin-5-yl)-1H-pyrrole-2-carbonitrile	DMR7OHB	Discovery agent	N.A.	Investigative	[29]
6-(3-Nitro-phenyl)-3H-benzothiazol-2-one	DM83VN6	Discovery agent	N.A.	Investigative	[31]
AL-43	DMLEDHR	Discovery agent	N.A.	Investigative	[32]
GSK-008A	DMC2ZF6	Gynecological disease	GA6Z	Investigative	[14]
GSK-1564023A	DMKN76P	Discovery agent	N.A.	Investigative	[33]
GSK-325971A	DM1865H	Discovery agent	N.A.	Investigative	[33]
GTPL8662	DMZQETV	Discovery agent	N.A.	Investigative	[34]
Lecanindole D	DMZ7OHP	Discovery agent	N.A.	Investigative	[35]
LGD-5552	DM67KWM	Discovery agent	N.A.	Investigative	[36]
ORG2058	DMH1M6N	Discovery agent	N.A.	Investigative	[14]
PF-02367982	DMZ5JNT	Endometriosis	GA10	Investigative	[30]
Tanaproget	DMQCW7V	Estrogen deficiency	FB83.0Y	Investigative	[37]
WAY-255348	DMSLNWA	Solid tumour/cancer	2A00-2F9Z	Investigative	[29]
ZK-112993	DM8JN45	Discovery agent	N.A.	Investigative	[38]
ZK-114043	DMBCPKE	Discovery agent	N.A.	Investigative	[39]
ZK-136798	DMCQYBE	Discovery agent	N.A.	Investigative	[40]
[3H]methyltrienolone	DMTSGOW	Discovery agent	N.A.	Investigative	[41]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Endometriosis	GA10	Endometrium tissue	1.71E-02	-1.47	-0.86
Osteoporosis	FA20	Bone marrow	5.03E-02	0.19	1.3
Uterine cancer	2C82	Endometrium tissue	3.26E-38	-3.79	-2.5
Preterm birth	KA21.4Z	Myometrium	5.89E-01	-0.03	-0.05

References

• [1] Clinical pipeline report, company report or official report of lipocine.
• [2] Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
• [3] Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
• [4] Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
• [5] Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
• [6] Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009 Jun;75(6):1317-24.
• [7] Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
• [8] Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7.
• [9] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [10] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [11] Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014 Nov 15;276(1-2):89-97.
• [12] ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health.
• [13] Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627).
• [15] Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8.
• [16] BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013 Aug;28(8):2253-64.
• [17] In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88.
• [18] Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992 Jun;42(5):457-65.
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033939)
• [20] Unusual base-catalyzed exchange in the synthesis of deuterated PF-2413873. Journal of Labelled Compounds. 08/2009; 52(10):435 - 442.
• [21] New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
• [22] Progesterone receptor antagonists Org 31710 and RU 486 increase apoptosis in human periovulatory granulosa cells. Fertil Steril. 2001 Dec;76(6):1225-31.
• [23] Bayer is seeking an exclusive licensee for its end-of-Phase I progestinagonist Bay 39-9624. Thepharmaletter. 29-04-2002.
• [24] New analogues of mifepristone with more dissociated antiprogesterone activities. J Steroid Biochem. 1989;34(1-6):413-7.
• [25] Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54.
• [26] Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. J Med Chem. 1998 Aug 27;41(18):3461-6.
• [27] Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):787-90.
• [28] 5-Aryl indanones and derivatives as non-steroidal progesterone receptor modulators. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6666-9.
• [29] Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
• [30] Optimisation of a pyrazole series of progesterone antagonists; Part 1. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3384-6.
• [31] Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading... J Med Chem. 2005 Aug 11;48(16):5092-5.
• [32] Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30.
• [33] The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2340-3.
• [34] A new strategy for selective targeting of progesterone receptor with passive antagonists. Mol Endocrinol. 2013 Jun;27(6):909-24.
• [35] The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144. J Nat Prod. 2009 Nov;72(11):1944-8.
• [36] Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
• [37] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [38] Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.Anticancer Res.1990 May-Jun;10(3):683-7.
• [39] Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998 Sep;158(3):401-7.
• [40] The antiovulatory activity of progesterone antagonists is not correlated to their antiprogestational potency in the rat. J Steroid Biochem Mol Biol. 1996 Sep;59(1):75-82.
• [41] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.